June 03, 2020
Alkahest has announced plans to launch a Phase 2 clinical trial that aims to address cognitive impairment and takes the unusual approach of using an external medical device that filters a harmful protein from the blood of end-stage renal disease patients. The medical device, known as an AKST1210, will be connected in-line with a haemodialysis...